Based on the aggregated intelligence of 120,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device maker Stryker (NYSE:SYK) has earned a coveted five-star ranking. Our data has shown that five-star stocks outperform the market by a significant margin; conversely, one-star stocks have woefully lagged the market average.

With that in mind, let's take a closer look at Stryker's business and see what CAPS investors are saying about the stock right now.

Stryker facts

Headquarters (founded)

Kalamazoo, Michigan (1941)

Market Cap

$15.18 billion

Industry

Health-care equipment

TTM Revenue

$6.66 billion

Management

CEO Stephen MacMillan (since 2005)

CFO Dean Bergy (since 2003)

Competitors

Zimmer Holdings (NYSE:ZMH)

Medtronic (NYSE:MDT)

CAPS members bullish on SYK also bullish on

Johnson & Johnson (NYSE:JNJ)

General Electric (NYSE:GE)

CAPS members bearish on SYK also bearish on

General Motors (NYSE:GM)

Microsoft (NASDAQ:MSFT)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, 220 of the 225 All-Star members who have rated Stryker -- or 98% -- believe the stock will outperform the S&P 500. These bulls include my Foolish colleague Brian Orelli (TMFBiologyFool) and saunafool, both of whom are ranked in the top 10% of our community.

Last month, Brian noted Stryker's sweet combination of growing sales and a falling price: "31 consecutive quarters of double-digit sales growth. You can't ask for much more of a long-term winner than that, yet it's down 30%."

In a pitch from three days ago, saunafool agreed, highlighting the long-term trend working in the stock's favor:

"Baby boomers are getting older, their knees and hips are wearing out, and the people who still have insurance will get the bad joints replaced. Meanwhile, [Stryker] is trading at levels not seen for years, even though they are still making money, have no debt, and will survive whatever the downturn brings."

What do you think about Stryker, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick. Microsoft is a selection of Inside Value. The Fool owns shares of Stryker.  The Fool's disclosure policy always gets a perfect score.